A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.

Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.

Start Date01 Jun 2025

Sponsor / Collaborator

Pharmazz, Inc.

CTRI/2024/07/070459

/ Not yet recruitingPhase 4

Safety and efficacy of sovateltide in acute cerebral ischemic stroke patients at a tertiary care centre-a double blinded block randomised placebo controlled study - NIL

Start Date22 Jul 2024

Sponsor / Collaborator

Pondicherry Institute of Medical Sciences

NCT05955326

/ RecruitingPhase 4

A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase IV Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

This is a prospective, multicenter, randomized, double-blind, parallel, phase IV study designed to evaluate the safety and efficacy of sovateltide (PMZ-1620, IRL-1620) as a potential treatment for cerebral ischemic stroke.

Start Date08 Jan 2024

Sponsor / Collaborator

Pharmazz, Inc.

100 Clinical Results associated with Sovateltide

100 Translational Medicine associated with Sovateltide

100 Patents (Medical) associated with Sovateltide

386

Literatures (Medical) associated with Sovateltide

01 Mar 2025·EXPERIMENTAL NEUROLOGY

Microglial cell proliferation is regulated, in part, by reactive astrocyte ETBR signaling after ischemic stroke

Article

Author: Torsney, Emily E ; LeComte, Matthew D ; Del Rio-Guerra, Roxana ; Poynter, Matthew E ; Spees, Jeffrey L ; McInnis, John J ; Reed, Leah F

Reciprocal communication between reactive astrocytes and microglial cells provides local, coordinated control over critical processes such as neuroinflammation, neuroprotection, and scar formation after CNS injury, but is poorly understood. The vasoactive peptide hormone endothelin (ET) is released and/or secreted by endothelial cells, microglial cells and astrocytes early after ischemic stroke and other forms of brain injury. To better understand glial cell communication after stroke, we sought to identify paracrine effectors produced and secreted downstream of astroglial endothelin receptor B (ETB_R) signaling. Using a genetic loss-of-function screen, we identified angiopoietin-2 (Ang-2) as a factor produced by reactive astrocytes in response to ET. In experiments with primary adult astrocytes stimulated by IRL1620, a specific ETB_R agonist, we found that ERK1/2 and NFkB mediated the effects of ET on Ang-2 production. To determine astroglial Ang-2 levels in vivo, reactive astrocytes expressing the high affinity glutamate transporter (GLAST, EAAT1) were isolated by magnetic-activated cell sorting 3 days after stroke. Astrocytes obtained from the ipsilateral hemisphere expressed significantly more Ang-2 compared with astrocytes isolated from the contralateral hemisphere, or from cortices of sham-operated (control) mice. Notably, analysis of microglia sorted from CX3CR1-eGFP mice demonstrated increased cell surface expression of Tie-2, the Ang-2 receptor, on cells obtained from ipsilateral versus contralateral tissue. Addition of recombinant Ang-2 to astrocyte-conditioned medium significantly increased the number of SIM-A9 murine microglial cells cultured under hypoxic conditions (1 % oxygen for 48 h). In transgenic GFAP-CreER™-EDNRB-^fl/fl mice with stroke, conditional knockout of astroglial ETB_R significantly decreased the number of proliferating cells in the peri-infarct area with a microglial phenotype (Ki67⁺/CD11b⁺). Our results indicate that Ang-2, and possibly other paracrine effectors functioning downstream of astroglial ETB_R signaling, are important mediators of microglial cell dynamics after stroke.

01 Dec 2024·DRUGS

Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial

Article

Author: Siddiqui, Mohd Shafat Imam ; Adwani, Sikandar Gokuldas ; Khurana, Dheeraj ; Sidhu, Gursaran Kaur ; Joshi, Deepika ; Karadan, Ummer ; Ramakrishnan, T C R ; Aralikatte, Saroja ; Rai, Hari Prakash ; Sundarachary, Nagarjunakonda Venkata ; Sharma, Mridul ; Vijaya, Pamidimukkala ; Jain, Dinesh ; Anand, Sidharth Shankar ; Vibha, Deepti ; Agrawal, Nilesh Radheshyam ; Gulati, Anil ; Pandian, Jeyaraj Durai ; Sardana, Vijay

BACKGROUND AND OBJECTIVES:

Sovateltide (Tycamzzi™), an endothelin-B (ET-B) receptor agonist, increases cerebral blood flow, has anti-apoptotic activity, and promotes neural repair following cerebral ischaemic stroke. The objectives of this study were to evaluate the efficacy and safety of sovateltide in adult participants with acute cerebral ischaemic stroke.

METHODS:

This was a randomised, double-blind, placebo-controlled, multicentre, Phase III clinical trial of sovateltide in participants with cerebral ischaemic stroke receiving standard of care (SOC) in India. Patients aged 18-78 years presenting up to 24 h after the onset of symptoms with radiologic confirmation of ischaemic stroke and a National Institutes of Health Stroke Scale score (NIHSS) of ≥ 6 were enrolled. Patients with recurrent stroke, receiving endovascular therapy, or with intracranial haemorrhage were excluded. The study drug (saline or sovateltide [0.3 µg/kg] was administered intravenously in three doses at 3 ± 1 h intervals on Days 1, 3, and 6, and follow-up was 90 days). The Multivariate Imputation by Chained Equations (MICE) was used to impute the missing assessments on the endpoints. An unpaired t-test, two-way analysis of variance with Tukey's multiple comparison test, and the Chi-square test were used for the statistical analysis. The objective was to determine at Day 90 (1) the number of patients with a modified Rankin Scale score (mRS) 0-2, and (2) the number of patients with an NIHSS 0-5 at 90 days.

RESULTS:

Patients were randomised with 80 patients in the sovateltide and 78 in the control group. Patients received the investigational drug at about 18 h of stroke onset in both control and sovateltide groups. The median NIHSS at randomisation was 10.00 (95% CI 9.99-11.65) in the control group and 9.00 (95% CI 9.11-10.46) in the sovateltide group. Seventy patients completed the 90-day follow-up in the control group and 67 in the sovateltide group. The proportion of intention-to-treat (ITT) patients with mRS 0-2 score at Day 90 post-randomisation was 22.67% higher (odds ratio [OR] 2.75, 95% CI 1.37-5.57); similarly, the proportion of patients with NIHSS score of 0-5 at Day 90 was 17.05% more (OR 2.67, 95% CI 1.27-5.90) in the sovateltide group than in the control group. An improvement of ≥ 2 points on the mRS was observed in 51.28% and 72.50% of patients in the control and sovateltide groups, respectively (OR 2.50, 95% CI 1.29-4.81). Seven of 78 patients (8.97%) in the control group and 7 of 80 (8.75%) in the sovateltide group developed intracranial haemorrhage (ICH). The adverse events were not related to sovateltide.

CONCLUSIONS:

The sovateltide group had a greater number of cerebral ischaemic stroke patients with lower mRS and NIHSS scores at 90 days post-treatment than the control group. This trial supported the regulatory approval of sovateltide in India, but a multinational RESPECT-ET_B trial will be conducted for US approval.

TRIAL REGISTRATION:

Clinical Trials Registry, India (CTRI/2019/09/021373) and the United States National Library of Medicine, ClinicalTrials.gov (NCT04047563).

01 Oct 2024·Neurocritical Care

The Effects of IRL-1620 in Post-ischemic Brain Injury: A Systematic Review and Meta-analysis of Experimental Studies

Review

Author: Xanthos, Theodoros ; Pouliakis, Abraham ; Iacovidou, Nikoletta ; Moustakas, Dimitris ; Mani, Iliana

BACKGROUND:

Sovateltide (IRL-1620), an endothelin B receptor agonist, has previously demonstrated neuroprotective and neuroregenerative effects in animal models of acute ischemic stroke. Recently, clinical trials indicated that it could also be effective in humans with stroke. Here, we systematically investigate whether IRL-1620 may be used for the treatment of ischemia-induced brain injury.

METHODS:

A systematic review was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. MEDLINE (PubMed) and Scopus databases were searched for eligible studies up to December 2022. The databases ClinicalTrials.gov and Pharmazz Inc. were screened for unpublished or ongoing trials. Only studies in English were evaluated for eligibility. Meta-analysis of the included studies was also conducted.

RESULTS:

Finally, seven studies were included in the review, all in animal rat models because of scarcity of clinical trials. Six studies, all in middle cerebral artery occlusion (MCAO) models, were selected for meta-analysis. In the two studies assessing mortality, no deaths were reported in the IRL-1620 group 24 h after MCAO, whereas the vehicle group had almost a five times higher mortality risk (risk ratio 5.3, 95% confidence interval 0.7-40.1, I² = 0%). In all five studies evaluating outcome on day 7 after MCAO, IRL-1620 was associated with statistically significantly lower neurological deficit and improved motor performance compared with the vehicle. Infract volume, differentiation potential of neuronal progenitor cells, and mitochondrial fate also improved with IRL-1620 administration.

CONCLUSIONS:

According to the above, in animal MCAO models, IRL-1620 enhanced neurogenesis and neuroprotection and improved outcome. Future studies are needed to expand our understanding of its effects in human study participants with acute ischemic stroke as well as in other common causes of cerebral ischemia including cardiac arrest.

News (Medical) associated with Sovateltide

26 May 2025

·www.echemi.com

Sun Pharma Amplifies Investment in Pharmazz to $25 Million, Elevating Stake to 22.7%

In a decisive move to bolster its presence in the biopharmaceutical sector, Sun Pharmaceutical Industries Ltd has announced an increased investment in U.S.-based Pharmazz Inc., raising its total commitment to $25 million and expanding its ownership stake to 22.7%. This strategic investment, structured in multiple tranches, is set to be completed by November 30, 2025. The initial tranche includes $10 million, along with the remaining $7.5 million from a prior SAFE (Simple Agreement for Future Equity) arrangement, to be invested by May 31, 2025. A subsequent $15 million tranche is scheduled for investment by November 30, 2025, or another mutually agreed date. Pharmazz is at the forefront of developing innovative treatments for critical care, with two leading drug candidates: Sovateltide, aimed at treating acute cerebral ischemic stroke, and Centhaquine, designed for hypovolemic shock. Both drugs have received approval in India and are marketed under the brand names Tyvalzi and Lyfaquin, respectively. These therapies are currently undergoing development for the U.S. and other international markets. With this enhanced investment, Sun Pharma secures an option to negotiate licensing rights for Sovateltide in certain developed markets, expanding upon its existing exclusive rights in select emerging markets. This move underscores Sun Pharma’s commitment to advancing its portfolio in critical care therapeutics and strengthening its global footprint in the pharmaceutical industry.

License out/inDrug Approval

24 May 2025

·pharma.economictimes.indiatimes.com

Sun Pharma to invest $25 mn in Pharmazz Inc; raises stake to 22.7 pc

New Delhi: Sun Pharmaceutical Industries Ltd on Friday said it has entered into an agreement with US-based Pharmazz Inc to invest up to USD 25 million, resulting in increasing its stake in the company to 22.7 per cent. The investment triggers conversion of earlier investment through SAFE (simple agreement for future equity) resulting in aggregate stake of up to 22.7 per cent in Pharmazz on a fully diluted basis, the company said in a regulatory filing. The first tranche of USD 10 million, along with the balance of USD 7.5 million out of SAFE tranche 2 investment, will be invested on or before May 31, 2025. The second tranche of USD 15 million will be invested on or before November 30, 2025 or such other mutually agreed date, it added. Pharmazz Inc is a biopharmaceutical company , developing two leading drug candidates , Sovateltide for treatment of acute cerebral ischemic stroke and Centhaquine for treatment of hypovolemic shock. Both products are approved in India and marketed through partners under brands Tyvalzi (Sovateltide) and Lyfaquin (Centhaquine), and are being developed for USA and other markets, it added. Subsequent to the investment, Sun Pharma will receive an option to negotiate licensing of Sovateltide for marketing and distribution in certain developed market countries. The company has already received exclusive right to licence Sovateltide for marketing and distribution in certain emerging market countries, it added.

License out/inDrug Approval

21 Aug 2024

·www.globenewswire.com

Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.

Strategic equity investment of $15 M to support completion of Pharmazz's pivotal Phase 3 study for Sovateltide to treat patients with acute cerebral ischemic strokeExpansion of the exclusive license agreement with Sun Pharma for marketing and distribution of Sovateltide in India to certain additional Emerging Market countries WILLOWBROOK, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz” or the “Company”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced that it has entered into an agreement with Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or affiliated companies) to support development of Sovateltide and extend the scope of its strong working relationship to commercialize a first-in-class innovative drug, Sovateltide (Tyvalzi™). Developed by Pharmazz for potential global use, Sovateltide is indicated for treating acute cerebral ischemic stroke in markets where it is launched. Pursuant to the agreement, Sun Pharma will make a strategic equity investment of $15 M in two tranches, subject to certain conditions, to support the development of Pharmazz's lead compound, Sovateltide, through a pivotal Phase 3 trial in the U.S. to treat patients with acute cerebral ischemic stroke. As the world's leading specialty generic pharmaceutical company, Sun Pharma’s equity investment further validates the promising developmental pathway for Sovateltide. Previously, Pharmazz entered into a license agreement with Sun Pharma to commercialize Sovateltide in India under Sun Pharma owned brand name Tyvalzi™. This collaboration is now being expanded to drive the asset’s commercialization efforts in certain additional Emerging Market countries. Sun Pharma’s investment and collaboration will bring valuable operational expertise and strategic inputs to the Pharmazz management team. About Sovateltide Sovateltide is a first-of-its-kind drug to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptoms. Pharmazz has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the study design and statistical analysis plan of its Phase 3 clinical trial of Sovateltide for treating acute cerebral ischemic stroke patients. The protocol is titled, “A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.” ClinicalTrials.gov ID: NCT05691244. Sovateltide is a first-in-class drug to treat acute cerebral ischemic stroke, a condition in which the loss of blood supply to the brain prevents brain tissue from receiving oxygen and nutrients, resulting in potential brain damage, neurological deficits, or death. Sovateltide promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis). Sovateltide also protects neural mitochondria and enhances their biogenesis. It can be given to patients along with thrombolytic, and about 30,000 acute cerebral ischemic patients have been treated in India. About Pharmazz, Inc. Pharmazz is a privately held company developing novel products in critical care medicine. Pharmazz obtained marketing authorization for two of its first-in-class drug molecules, Centhaquine and Sovateltide, for hypovolemic shock and acute cerebral ischemic stroke, respectively, in India. In addition, the U.S. Food and Drug Administration (FDA) has approved two phase III INDs for Centhaquine as an agent for hypovolemic shock and Sovateltide for acute cerebral ischemic stroke. Additional information may be found on the Company’s website, www.pharmazz.com, and follow us on LinkedIn & X (Formerly Twitter). About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050): Sun Pharma is the world’s leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma’s high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company’s vertically integrated operations deliver high quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter). Disclaimer: Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be “forward-looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. Contacts: Pharmazz, Inc. Investors Media David Costello Shruti Gulati Tel+1 630 780 6087Tel+1 630 780 6087E maildavid.costello@pharmazz.comE mailshruti.gulati@pharmazz.com

Phase 3License out/inDrug Approval

100 Deals associated with Sovateltide

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06138

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Ischemic Stroke	India	Pharmazz, Inc.	31 May 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	India	Pharmazz, Inc.	23 Aug 2022
Brain Infarction	Phase 3	India	Pharmazz, Inc.	10 Nov 2019
Solid tumor	Phase 3	United States	Pharmazz, Inc.	25 Dec 2016
Asphyxia Neonatorum	Phase 2	India	Pharmazz, Inc.	06 Sep 2023
Hypoxia-Ischemia, Brain	Phase 2	India	Pharmazz, Inc.	06 Sep 2023
Neonatal encephalopathy	Phase 2	India	Pharmazz, Inc.	06 Sep 2023
Asphyxia	Phase 2	United States	Pharmazz, Inc.	23 Aug 2022
Asphyxia	Phase 2	India	Pharmazz, Inc.	23 Aug 2022
acute spinal cord injury	Phase 2	India	Pharmazz, Inc.	10 Jan 2019
Non-Small Cell Lung Cancer	Phase 2	United States	Spectrum Pharmaceuticals, Inc.	01 May 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


sovateltide (ISC2025)	Not Applicable	Stroke	-	Sovateltide	izmpkvswdm(tddpbygasd) = vugmrpbqql jcgfedppns (nyukarfvwz ) View more	Positive	30 Jan 2025
				Saline	izmpkvswdm(tddpbygasd) = vdwmbqnzyv jcgfedppns (nyukarfvwz ) View more
NCT04047563 (CTRI/2019/09/021373, Pubmed \| Drugs) Manual	Phase 3	Acute Ischemic Stroke	158	Sovateltide	zpkjnrgzau(ffjauuxhrb) = lsvsvjaojd funzxxicuz (ujybkjdbhp ) View more	Positive	15 Nov 2024
				Control (Placebo)	lbweawzkpt(clhqveuypg) = sqdfjxvzoq kudspccjux (kdbjkyvlpr ) View more
NCT04047563 (GlobeNewswire) Manual	Phase 3	Acute Ischemic Stroke	158	Sovateltide	icyhvgsyhh(ejzkclzpdu) = colffkzphe jmstzjyxvf (tusurwplvu ) View more	Positive	31 Oct 2022
				Placebo	icyhvgsyhh(ejzkclzpdu) = uybmepcvzs jmstzjyxvf (tusurwplvu ) View more
NCT04047563 (Biospace) Manual	Phase 3	Acute Ischemic Stroke	158	standard of care+Sovateltide	vvwhwsmlix(geuaadsgqy) = improvement of ≥6 points on NIHSS jybyevjyok (rxuxlclzyz ) View more	Positive	25 May 2022
				standard of care+Placebo
NCT04052737 (PRNewswire) Manual	Phase 2	Alzheimer Disease	62	sovateltide	lzlidgieyw(vnrpfwvely) = ncrmtpnbup vjhajpsowv (nolywkpvuo, 0.955) View more	Positive	10 Jun 2021
				Placebo	lzlidgieyw(vnrpfwvely) = gbadpdcnpi vjhajpsowv (nolywkpvuo, 0.920) View more
NCT04046484 (Pubmed \| CNS Drugs) Manual	Phase 2	Ischemic stroke	36	Sovateltide	ppqhrzbjdq(qtsfqzdgdm) = zcdystyiha vegedapkhf (oggzeikcck ) View more	Positive	01 Jan 2021
				Placebo	ppqhrzbjdq(qtsfqzdgdm) = vfexnzebvj vegedapkhf (oggzeikcck ) View more
AAIC2018	Not Applicable	Alzheimer Disease	-	IRL-1620	pnwzfdspba(mudpnpxohr) = kpolsezplg imhtkvgddc (spvcmtjapa ) View more	-	01 Jul 2018
				Vehicle	pnwzfdspba(mudpnpxohr) = txhhnawwsx imhtkvgddc (spvcmtjapa ) View more
NCT05691244 (Pubmed \| Brain Res)	Phase 3	Brain Ischemia	-	IRL-1620	fbicdkjkup(apcpgkuvhn) = odgiopnnaj cfjbtkrifr (hpnqeskccr )	-	29 Jun 2012
				Vehicle	fbicdkjkup(apcpgkuvhn) = hfnafacpxv cfjbtkrifr (hpnqeskccr )
NCT05691244 (Pubmed \| Brain Res)	Phase 3	Infarction, Middle Cerebral Artery	-	IRL-1620	nvqaajotph(hmumeidtgh) = nmyqvnglnk sjkbtlwflp (cjmfasbkay )	-	28 Oct 2011
				BQ788	nvqaajotph(hmumeidtgh) = xndqzglunq sjkbtlwflp (cjmfasbkay )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis